BioPharmSignal logoBioPharmSignal

Biotech News

ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities

ImmunityBio (IBRX)ImmunityBioEarnings

Preliminary Q1 2026 net product revenue of approximately $44.2 million, representing an ~168% year-over-year increase compared with Q1 2025 Consistent quarter-over quarter revenue growth since commercial launch, reflecting continued adoption of ANKTIVA ® by U.S.

Open original release

Related news

IBRXImmunityBio2026-05-07 11:30 EST

ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million

IBRXImmunityBio2026-06-01 17:51 EST

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

ARGXArgenx2026-07-23 05:00 EST

argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update

IMTXImmatics2026-05-12 11:00 EST

Immatics Announces First Quarter 2026 Financial Results and Business Update

LEGNLegend Biotech Corporation2026-05-12 11:00 EST

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

CHRSCoherus BioSciences, Inc.2026-05-11 20:05 EST

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

ELVNEnliven Therapeutics2026-05-07 20:05 EST

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

ARGXArgenx2026-05-07 05:00 EST

argenx Reports First Quarter 2026 Financial Results and Provides Business Update

BMYBMYBristol-Myers Squibb Company2026-06-18 10:59 EST

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

KURAKura Oncology2026-05-12 20:02 EST

Kura Oncology Reports First Quarter 2026 Financial Results

View all latest news

ImmunityBio

ImmunityBio is an immunotherapy company focused on cancer and immune-system activation, with a portfolio spanning cell therapy and biologics. Its story is built around creating broad anti-cancer immune responses.

Recent company news

IBRXImmunityBio2026-06-01 17:51 EST

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

IBRXImmunityBio2026-05-22 11:30 EST

ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation

IBRXImmunityBio2026-05-22 11:30 EST

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS

IBRXImmunityBio2026-05-20 00:30 EST

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

IBRXImmunityBio2026-05-19 11:30 EST

ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026

Stock data

Close
6.99 USD
Market cap
7.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States